Short answer
Tvardi Therapeutics, Inc. (TVRD) filed an 8-K current report with the SEC on November 19, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). TTI-109 advanced toward an Investigational New Drug filing for inflammatory bowel disease.
Tvardi Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- TTI-109 advanced toward an Investigational New Drug filing for inflammatory bowel disease
- FDA pre-IND feedback supports continued development of Tvardi’s next-generation oral STAT3 inhibitor
- Milestone may reduce regulatory uncertainty, but clinical efficacy and safety remain unproven
- Full program details and FDA feedback are in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- FDA pre-IND feedback supports Phase 2 development approach for TTI-109 in ulcerative colitis and Crohn’s disease
- IND submission planned for 2027, with Phase 2 initiation contingent on FDA clearance and additional funding
- Phase 1 exposure analysis supports sustained STAT3 inhibition at proposed doses with minimal predicted STAT1 and STAT5 effects
- Potential differentiation from JAK inhibitors through narrower STAT3 targeting, though patient safety and clinical benefit remain unproven
- Regulatory progress advances TTI-109 toward clinical testing but increases dependence on financing availability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tvardi Therapeutics, Inc. 8-K filings
Get the next TVRD 8-K as it lands
Follow TVRD for push alerts, or ask the research agent what this filing means.